Hardening of the skin in systemic sclerosis impairs patients' ability to care for their own teeth properly. As a result, this study suggests, dental issues may be prognostic indicators.
The biologic adalimumab improves pain and physical function in a randomized trial of patients with peripheral spondyloarthritis unable to take non-steroidal anti-inflammatory drugs.
People have been busy creating decision aids to help involve patients in treatment choices. But rheumatologists prove lukewarm to the whole idea so far.
Two studies suggest that prolonged morning stiffness is linked with disease course in rheumatoid arthritis. Should it be added to criteria sets?
Bone erosions found at a rheumatoid arthritis (RA) patient’s baseline exam are harbingers of future joint damage and more severe disease. As to why this is so, new studies offer only hints.
A small prospective study finds that patients with psoriatic arthritis eventually revert to disease if TNF-alpha drugs are discontinued, sometimes as much as 6 months later.
Analysis of data from clinical trials as TB screening protocols changed shows the value of testing for tuberculosis when treating patients for rheumatoid or psoriatic arthritis or spondyloarthropathies with certolizumab pegol.
Nearly half of rheumatoid arthritis patients were able to retain remission for 3 months on a 25 mg weekly dose plus methotrexate. Returning to full dose quickly resolved disease for those who flared.
Patients with rheumatoid arthritis face an increased risk for acute coronary syndromes, but a popular statin seems to reduce asymptomatic carotid plaques.
More good news for Actemra: rheumatoid arthritis patients can safely transition from the intravenous form of the IL-16 blocker to the injectable version.